|
|
Best of Lipid Forum®: Examining the Role of Lp(a) as a Risk Factor in Atherosclerotic Cardiovascular Disease
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein particle that is associated with poor cardiovascular prognosis due to its pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Unfortunately, traditional lipid-lowering therapy does not provide sufficient Lp(a) reduction. High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) through mechanisms associated with increased atherogenesis, inflammation, and throm... |
|
|
Best of Lipid Forum®: Examining the Role of Lp(a) as a Risk Factor in Atherosclerotic Cardiovascular Disease
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein particle that is associated with poor cardiovascular prognosis due to its pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Unfortunately, traditional lipid-lowering therapy does not provide sufficient Lp(a) reduction. High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular diseases (ASCVD) through mechanisms associated with increased atherogenesis, inflammation, and thro... |
|
|
Understanding Cholesterol Guidelines and Implementing Non-statins in High-Risk Populations: Paired Conversations and Case Vignettes
An interprofessional faculty of primary care and specialty clinicians discuss real-world issues in managing patients with complex and challenging dyslipidemia, including elevated lipoprotein a (Lp(a)). Several paired conversations serve as the foundation for discussions related to recent cholesterol guidelines, patient risk stratification, and recommended goals for patients at risk of atherosclerotic cardiovascular disease. Two case vignettes provide the basis for robust discussion among the f... |
|
|
Clinical Questions in Cardiology: Using Glucagon-like Peptite-1 Receptor Agonists
The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications has become an important option for treating patients with type 2 diabetes mellitus (T2D). Cardiovascular outcome trials also show that selected GLP-1RAs exert beneficial cardiovascular benefits in patients with and without T2D. In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and th... |
|